Cn-105

Cn-105

SCHEMBL16189774

CC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 3/20 0.47
NPY4R P50391 13/20 0.43
NPY1R P25929 8/20 0.43
NPY5R Q15761 8/20 0.43
NPY2R P49146 5/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
TFPI P10646 1/20 0.41
TLR2 O60603 1/20 0.41
NMT2 O60551 1/20 0.39
NMT1 P30419 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cn-105 SCHEMBL20439448 1.00 SIRT5 (0.47) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL20439464 0.98 SIRT5 (0.51) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL16189767 0.95 TLR2 (0.48) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL20439438 0.95 TLR2 (0.48) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL20439410 0.94 TLR2 (0.49) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL16189773 0.92 SIRT5 (0.43) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL20439405 0.92 SIRT5 (0.43) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL23879904 0.90 SIRT5 (0.45) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL12035273 0.88 SIRT5 (0.44) SIRT5NPY4RNPY1RNPY5RNPY2R
SCHEMBL16189768 0.87 NMT2 (0.46) SIRT5SIRT2TFPITLR2NMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395342-A1 PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION UNIV DUKE (US) 2021-12-23 US disclosed
US-11136371-B2 Peptide compounds for suppressing inflammation DUKE UNIVERSITY (US) 2021-10-05 US disclosed
US-20190194296-A1 PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION UNIV DUKE (US) 2019-06-27 US disclosed
US-10280210-B2 Peptide compounds for suppressing inflammation DUKE UNIVERSITY (US) 2019-05-07 US disclosed
WO-2018140563-A1 USE OF APOE MIMETIC PEPTIDES FOR REDUCING THE LIKELIHOOD OF EPILEPTOGENESIS DUKE UNIVERSITY (US) 2018-08-02 WO disclosed
US-20160244507-A1 PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION UNIV DUKE (US) 2016-08-25 US disclosed
US-9303063-B2 Peptide compounds for suppressing inflammation DUKE UNIVERSITY (US) 2016-04-05 US disclosed
US-20140315823-A1 PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION DUKE UNIVERSITY (US) 2014-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280210-B2 Peptide compounds for suppressing inflammation APOB, IAPP, CCL2 SIRT5 3974/4885NPY4R 722/4885NPY1R 652/4885
US-20210395342-A1 PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION APOB, IAPP, CCL2 SIRT5 3974/4885NPY4R 722/4885NPY1R 652/4885
US-11136371-B2 Peptide compounds for suppressing inflammation APOB, IAPP, CCL2 SIRT5 3974/4885NPY4R 722/4885NPY1R 652/4885
US-20190194296-A1 PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION APOB, IAPP, CCL2 SIRT5 3974/4885NPY4R 722/4885NPY1R 652/4885
US-20140315823-A1 PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION APOB, IAPP, CCL2 SIRT5 3974/4885NPY4R 722/4885NPY1R 652/4885
US-20160244507-A1 PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION APOB, IAPP, CCL2 SIRT5 3974/4885NPY4R 722/4885NPY1R 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.